China-based medical equipment company Valgen Medtech presented the 12-month results of the DRAGONFLY-DMR trial during the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) 2023.
DragonFly is a transcatheter-edge-to-edge repair (TEER) therapy that has been successfully implanted in more than 300 patients in China.
The trial contributes to increasing evidence supporting the safety and efficacy of TEER therapy, and specifically the DragonFly mitral valve repair system, for treating patients with chronic symptomatic 3+ to 4+ degenerative mitral regurgitation (DMR) at prohibitive surgical risk.
